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ORIGINAL ARTICLE
Hypothesis: Although smoking is the major risk factor for non–
small-cell lung cancer (NSCLC), other factors are also associated 
with lung carcinogenesis, such as wood-smoke exposure (WSE). 
This article has been aimed at suggesting that lung cancer related 
to cigarette smoking and lung cancer related to WSE have different 
clinical and genetic characteristics.
Experimental Design: A cohort of 914 lung cancer patients was 
prospectively studied; they had been treated at Mexico’s National 
Cancer Institute between 2007 and 2010. The associations of WSE 
and cigarette smoking with clinical characteristics, mutation profile, 
response to chemotherapy, and epidermal growth factor receptor 
tyrosine kinase inhibitors were analyzed, and overall survival (OS) 
rate was calculated. The trial was registered with ClinicalTrials.gov: 
NCT01023828.
Results: Of the lung cancer patients studied, 95.1% were classified 
as coming within the NSCLC histology subtype; 58% of the patients 
smoked cigarettes, 35% had a background of WSE (exposure to both 
cigarette smoke and wood smoke was documented in 12.1% of all 
patients), and 19.4% patients had no smoke-exposure background. 
WSE was associated with NSCLC and adenocarcinoma histology, 
and was also more frequently associated with epidermal growth 
factor receptor-mutations than cigarette-smoking patients were 
(50.0% cf. 19.4%), whereas KRAS mutations were less common in 
WSE patients (6.7%) than in smokers (21%). WSE patients had a 
higher epidermal growth factor receptor tyrosine kinase inhibitor 
response rate (39.7%) than smokers (18.8%). The NSCLC patient 
WSE group’s OS was longer (22.7 months) than that for smokers 
(13.8 months).
Conclusion: NSCLC patients who smoked tobacco/cigarettes dif-
fered from those having a background of WSE regarding tumor 
histology, mutation profile, response rate, and OS, indicating that 
different carcinogenic mechanisms were induced by these two types 
of smoke exposure.
Key Words: NSCLC, Wood-smoke exposure, Outcome, Mutational 
profiles.
(J Thorac Oncol. 2012;7: 1228–1234)
Lung cancer is the leading cause of cancer-related mortal-ity worldwide.1 Mean annual cancer-related mortality 
in Mexico from 1998 to 2004 was 397,400; 45,578 of these 
deaths resulted from lung cancer.2 Non–small-cell lung cancer 
(NSCLC) accounts for approximately 85% of all lung cancers; 
it consists of several subtypes, predominantly adenocarci-
noma, squamous-cell lung cancer, and large-cell lung cancer.3
 Cigarette smoking is the most common etiological factor 
for lung cancer, accounting for nearly 85% of all patients in the 
United States and Europe but only 66% in Mexico.4 Some other 
well-described environmental factors contribute toward lung 
carcinogenesis, such as exposure to asbestos, fine particulate 
air pollution, radon, arsenic compounds, cadmium, chromium, 
ionizing radiation, and chronic wood-smoke exposure (WSE).5
Wood is burned for heating and cooking6; epidemiological 
studies have linked WSE with increased prevalence of 
respiratory disease and increased mortality in countries in Asia, 
Africa, the Americas, and even some European countries.7,8 
Long-term exposure to wood smoke for more than 50 years 
has been associated with an increased risk of lung cancer in 
Mexico.9 Wood byproducts are known carcinogens and have 
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been reported to lead to increased p53 phosphorylation10 and 
gene promoter methylation of the p16 and GATA4 genes.11
Clinical trials have shown that lung cancer patients 
having epidermal growth factor receptor (EGFR) mutations 
respond better to EGFR tyrosine kinase inhibitors (TKIs)12; by 
contrast, the presence of KRAS mutations is associated with a 
lack of response.13,14 Our group conducted a clinical trial using 
EGFR-TKIs as treatment for patients having progression to 
first- or second-line chemotherapy; 28% of the patients in our 
group had a history of WSE and were associated with bet-
ter EGFR-TKI response rate (RR) (83.3%) and improved 
progression-free survival (PFS) of 17.6 months.15 The clinical 
and pathological characteristics, genotype (EGFR and KRAS), 
and response to chemotherapy, EGFR-TKIs, and clinical 
outcomes were investigated regarding lung cancer patients at 
our institution.
PATIENTS AND METHODS
Patient Selection
All patients treated for lung cancer at the Lung Cancer 
Clinic (Instituto Nacional de Cancerología—INCan) of 
Mexico from 2007 to 2010 were evaluated. A complete medi-
cal history, including a very detailed history of smoking, 
smoke exposure, and physical examination, was obtained; 
tumor specimens were collected at the time of diagnosis. WSE 
was defined as being exposed to fumes resulting from burning 
wood in fireplaces and wood stoves for more than 5 years for 
at least 4 hours per day.16 The WSE index was calculated by 
multiplying the number of daily hours exposed by the number 
of years’ exposure. A nonsmoker was defined as being some-
one having a lifetime exposure of less than 100 cigarettes17; 
the tobacco-smoking index was calculated by multiplying the 
number of cigarette packs consumed per day by the number 
of years spent smoking. This study was approved by INCan’s 
Review Board and Ethics Committee (077/055/OMI-2007) 
and registered with ClinicalTrials.gov: NCT01023828.
Tissue Procurement
Selecting the procedure for obtaining a biopsy from 
all patients depended on patient and tumor characteristics. 
Biopsies involved using computed tomography-guided tru-
cut needle, open thoracoscopy, or fiber optic bronchoscopy. 
INCan and National Institute of Respiratory Diseases pathol-
ogy departments gave a histologic diagnosis of samples and 
quantified neoplastic cellularity; samples were later embed-
ded in paraffin until processing for DNA extraction.
DNA Extraction and Mutational Analysis
Genomic DNA was extracted by standard procedure 
from areas of paraffin slides containing more than 50% 
tumor using the QIAamp DNAFFPE Tissue Kit, accord-
ing to the manufacturer’s instructions. EGFR (exons 18–21) 
and KRAS gene mutations from some samples were detected 
by Therascreen RGQ PCR Kit (QUIAGEN, Mexico D.F., 
Mexico; Scorpions ARMS method), according to the manu-
facturer’s instructions.
Statistical Analysis
Continuous variables were summarized as arithmetic 
means, medians, and SDs for descriptive purposes, and cate-
gorical variables were expressed as percentages with 95% con-
fidence intervals (CIs). Student’s t or Mann-Whitney U tests 
were used for inferentially comparing two groups, according to 
data distribution determined by Kolmogorov-Smirnov test, and 
analysis of variance and Tukey test or Kruskal Wallis tests for 
comparing two groups. Fisher’s exact or χ2 tests were used for 
assessing categorical variable significance. Statistical signifi-
cance was determined as p value less than  0.05 using a two-
tailed test. Statistically significant and borderline significant 
variables (p < 0.1) were included in multivariate logistic regres-
sion analysis. Overall survival (OS) was measured from day of 
diagnosis to date of death or last follow-up visit and analyzed 
by Kaplan-Meier technique; subgroups were compared using 
the log-rank test. All variables were dichotomized for survival 
curve analysis. Cox multivariate analysis was used for adjusting 
for potential confounders. Data was analyzed using SPSS soft-
ware package, version 15 (SPSS, Inc., Chicago, IL).
RESULTS
General Characteristics
Nine hundred and fourteen lung cancer patients were 
analyzed; mean age was 61 ± 12.2 years, 47.9% were women 
and 52.1% men. Cigarette smoking was present in 57.8% of 
patients (22 ± 36 mean smoking index). Of the total number of 
patients, 34.6% had a background of WSE (53.5 ± 135 mean 
WSE index); only 45.8% had a history of exclusively smoking 
cigarettes, and 22.7% exclusively of WSE. Exposure to both 
cigarette smoke and wood smoke was documented in 12.1% of 
patients, and 19.4% had no WSE at all. NSCLC histology was 
observed in 95.1% of patients (69.5% adenocarcinoma, 17% 
squamous-cell carcinoma, 2.6% large-cell carcinoma, and 
6% others) whereas small-cell lung cancer was observed in 
4.9% of cases. Clinical stage distribution (as per the American 
Joint Committee on Cancer 2010) was 76.4% stage IV, 22.6% 
stage III, and only 1% in stages I and II. Early diagnosis is dif-
ficult in Mexico because patients arrive in already advanced 
stages of the disease. Of the patients, 68.4% had 0 or 1 as per 
Eastern Cooperative Oncology Group (ECOG). EGFR muta-
tions were diagnosed in 368 NSCLC patients (42.3%), 30.8% 
of the samples being positive; it was a fair sampling of the gen-
eral population and was not biased in favor of one exposure 
group or histologic group. The most common EGFR mutation 
was exon 19 deletion (65.8%), followed by exon 18 (9.2%), 21 
single-point mutations (26%), and T790M mutation in 2.1% 
of patients. KRAS mutation was determined in 232 patients 
(26.6%), having a positive result in 16.5% of cases.
Clinical and Pathological Characteristics 
Associated With Cigarette-Smoking and WSE
Table 1 shows the clinical pathological and molecular 
characteristics related to exposure history in all patients. WSE was 
more common in women (82.9%); non smoke exposure patients 
were younger than WSE ones or smokers. SCLC histology risk was 
lower among WSE patients and those having smoking exposure 
1230 Copyright © 2012 by the International Association for the Study of Lung Cancer
Arrieta et al. Journal of Thoracic Oncology  •  Volume 7, Number 8, August 2012
TABLE 1.  Clinical Pathological and Molecular Characteristics Related to Exposure History in All Patients
Variable
Exposure
pNone Smoking Wood Smoke Smoking and Wood Smoke
Sex
 Male 57 (32.2) 309 (73.7) 36 (17.1) 73 (67.3) <0.0001
 Female 120 (67.8) 110 (26.3) 174 (82.9) 35 (32.7) —
Age 57.4 ± 13.2 60.2 ± 11.5 61.3 ± 12.0 62.3 ± 12.7 0.003
0.05a
0.011b
0.005c
0.705d
0.36e
0.893f
Diagnosis
 Small-cell lung cancer 6 (3.4) 34 (7.5) 4 (1.4) 4 (3.7) 0.006
 Non–small-cell lung cancer 171 (96.6) 385 (92.5) 206 (98.6) 104 (96.3) —
Histological subtype
 Adenocarcinoma 142 (80.6) 249 (60.0) 174 (83.6) 65 (59.8) —
 Squamous-cell carcinoma 16 (8.6) 92 (21.7) 20 (9.2) 29 (27.1) —
 Large-cell carcinoma 3 (1.7) 20 (4.1) 4 (1.4) 3 (2.8) <0.0001
 Others (undifferentiated, adenosquamous etc) 10 (5.7) 28 (6.8) 9 (4.3) 7 (6.5) —
 Small-cell lung cancer 6 (3.4) 30 (7.3) 3 (1.4) 4 (3.7) —
ECOG
 0 15 (8.7) 56 (12.7) 35 (16.2) 17 (15.0) —
 1 101 (58.7) 222 (53.5) 112 (53.9) 64 (59.8) —
 2 36 (20.9) 107 (25.6) 45 (21.1) 19 (17.8) 0.480
 3 18 (10.5) 30 (7.2) 16 (7.8) 6 (5.6) —
 4 2 (1.2) 4 (1.0) 2 (1.0) 2 (1.9) —
Stage
 I 0 (0) 0 (0) 2 (0.5) 0 (0) —
 II 4 (2.3) 5 (0.7) 0 (0) 1 (0.9) —
 IIIa 8 (4.6) 33 (6.9) 9 (3.9) 6 (5.5) 0.277
 IIIb 25 (13.3) 74 (17.3) 40 (19.0) 21 (19.3) —
 IV 140 (79.8) 307 (75.1) 159 (76.6) 80 (74.3) —
Metastasis
 Contralateral lung 57 (34.5) 121 (30.2) 51 (39.4) 0 (0) 0.066
 Bone 50 (30.3) 103 (25.6) 49 (21.0) 33 (23.9) 0.232
 Central nervous system 35 (21.1) 94 (23.4) 45 (19.5) 33 (23.9) 0.683
 Liver 21 (12.7) 44 (11.0) 21 (7.5) 13 (5.5) 0.127
 Nonregional lymph nodes 27 (16.4) 68 (17.0) 34 (14.5) 26 (19.3) 0.741
 Adrenal glands 3 (1.8) 24 (6.0) 10 (3.0) 3 (2.8) 0.070
Signs and symptoms
 Dyspnea 90 (54.2) 203 (50.9) 117 (57.9) 56 (52.8) 0.434
 Cough 121 (72.9) 283 (70.9) 142 (70.3) 81 (76.4) 0.662
 Weight loss 66 (40.0) 170 (42.6) 103 (51.0) 58 (54.7) 0.024
 Hemoptysis 17 (10.3) 80 (20.1) 38 (18.8) 22 (20.8) 0.05
 Thoracic pain 62 (37.6) 154 (38.6) 94 (46.5) 55 (51.9) 0.027
 Pleural efussion 66 (39.5) 96 (24.1) 96 (47.8) 30 (28.3) <0.0001
EGFR mutation
 Positive 25 (27.5) 18 (12.9) 51 (55.4) 17 (40.5) <0.0001
 Exon 18 (G719 C/S/A) — — — — —
 Exon 19 (deletions) — — — — —
 Exon 20 (S768I) — — — — —
 Exon 21 (L858R) — — — — —
 Negative 66 (72.5) 122 (87.1) 41 (44.6) 25 (59.5) —
(Continued)
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history; non smoke exposure and WSE patients had increased 
adenocarcinoma histology and pleural effusion frequency when 
diagnosed with NSCLC. Weight loss and chest pain were more 
frequent in WSE patients than in other groups, while patients 
having a history of cigarette-smoking had an increased frequency 
of hemoptysis. Supplemental Digital Content 1 http://links.lww.
com/JTO/A289) shows clinical, pathological and molecular 
characteristics according to exposure history.
Mutation-Frequency Analysis
EGFR mutations were found more frequently among 
patients with no smoke exposure, WSE, and WSE with ciga-
rette-smoking background (27.5% [95%CI 18.33-36.7], 40.5% 
[32.95-48.05] and 55.4% [45.18-65.61], respectively) when 
compared with cigarette-smoking patients (12.9% [7.05 -18.75]); 
however, KRAS-mutation frequency was significantly higher 
in cigarette-smoking patients (28% [18.86 -37.12]) than other 
groups. Only in EGFR mutated patients there was no relation-
ship between EGFR-mutation type from the mutation in the 
exons 18 to 21 and smoke-exposure history (Table 2).
EGFR mutation-associated factors were: being female 
(38.3 cf. 22.0: p = 0.001), having WSE (50.8 cf. 19.8: p < 
0.001), a no smoke-exposure history (40.8 cf. 21.1: p < 0.001), 
and adenocarcinoma histology (35.7 cf. 13.9 p < 0.001). Only 
adenocarcinoma histology (hazard ratio 2.81; 1.37–5.72 95% 
CI; p = 0.005) and WSE (3.46:;2.1–5.7 95% CI; p < 0.01) 
remained significant in multivariate analysis.
KRAS-mutation–associated factors were: age 60 years 
or older (21.5 cf. 11.9; p = 0.054), adenocarcinoma histol-
ogy (35.7 cf. 13.9; p = 0.001), cigarette-smoking (23.7 cf. 9.0; 
TABLE 2.  Type of Mutations in EGFR and KRAS
Variable Exposure
pAll Genotyping Patients None (%) Smoking Wood Smoke (%) Smoking and Wood Smoke
EGFR mutation
 Exon 18 (G719 C/S/A) 1 (9.1) 2 (18.2%) 6 (54.5) 2 (18.2%) 0.074
 Exon 19 (Deletions) 23 (30.3) 12 (15.8%) 34 (44.7) 7 (9.2%) 0.001
 Exon 20 (T790M) 1 (12.5) 2 (25.0%) 3 (37.5) 2 (25.0%) 0.407
 Exon 20 (S768I) 2 (20.0) 4 (40.0%) 3 (30.0) 1 (10.0%) 0.966
 Exon 21 (L858R) 6 (19.4) 6 (19.4%) 12 (38.7) 7 (22.6%) 0.016
KRAS mutation
 Codon12 7 (20) 23 (65.7) 3 (8.6) 2 (5.77) 0.009
 Codon 13 0 (0) 0 (0%) 1 (100) 0 (0) 0.685
Only EGFR Mutated 
Patients
None Smoking Wood Smoke Smoking and Wood Smoke p
EGFR mutation
 Exon 18 (G719 C/S/A) 1 (9.1) 2 (18.2%) 6 (54.5) 2 (18.2) 0.599
 Exon 19 (Deletions) 23 (30.3) 12 (15.8%) 34 (44.7) 7 (9.2) 0.125
 Exon 20 (T790M) 1 (12.5) 2 (25.0%) 3 (37.5) 2 (25.0) 0.642
 Exon 20 (S768I) 2 (20.0) 4 (40.0%) 3 (30.0) 1 (10.0) 0.305
 Exon 21 (L858R) 6 (20.0) 6 (20.0%) 11 (36.7) 7 (23.3) 0.296
Only KRAS mutated patients
 Codon 12 7 (18.9) 25 (67.6%) 3 (8.1) 2 (5.4) 0.925
 Codon 13 0 (0) 0 (0%) 1 (100) 0 (0) 0.925
EGFR, epidermal growth factor receptor.
TABLE 1.  (Continued)
Variable
Exposure
pNone Smoking Wood Smoke Smoking and Wood Smoke
KRAS mutation
 Positive 7 (11.1) 26 (28.0) 3 (6.0) 2 (7.4) 0.001
 Negative 56 (88.9) 67 (72.0) 47 (94.0) 25 (92.6) —
aNone vs. smoking.
bNone vs. WSE.
cNone vs. smoking and WSE.
dSmoking vs. WSE.
eSmoking vs. Smoking and WSE.
fWSE vs. WSE and smoking.
ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; WSE, wood-smoke exposure.
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p < 0.003), and absence of WSE (21.4 cf. 6.8; p = 0.006). Only 
cigarette-smoking (2.85; 1.28–6.36 95% CI; p = 0.010) and 
WSE absence (0.3; 0.11–0.83 95% CI; p = 0.021) remained 
significant in multivariate analysis.
Chemotherapy and EGFR-TKI Response Rate
Among the of patients, 81.9% received systemic che-
motherapy and 31.2% EGFR-TKIs. Overall response to 
platinum-based therapy was 37.8%. There were no differ-
ences in response regarding exposure groups’ background 
(Table 3). Overall response to EGFR-TKIs (gefitinib and 
erlotinib) was 26.9%; a history of WSE and absence of 
cigarette-smoking history were factors associated with this 
response (Table 3).
Overall Survival
Survival data were obtained for all patients. Median 
follow-up was 6.9 ± 13.5 months, and median OS was 16.9 
months; median follow-up was brief because the patients were 
recent. Factors associated with longer OS were: being female, 
good ECOG (0 or 1), clinical stage at diagnosis (III cf. IV), 
adenocarcinoma histology, and history of exposure (Table 4 
and Fig. 1). Only sex, ECOG, and clinical stage remained sig-
nificant in multivariate analysis. Table 4 shows all the factors 
associated with OS.
DISCUSSION
Both WSE and cigarette smoking are known causes of 
pulmonary diseases such as chronic bronchitis and pulmonary 
TABLE 3.  Response to Treatments for All Patients
Exposure
Response to CT Response to EGFR-TKIs
N Negative (%) Positive (%) p N Negative (%) Positive (%) p
None 136 64 36 0.911 66 72.7 27.3 <0.001
Smoking 291 62.9 37 94 68.3 11.7
WSE 139 60.4 39.6 60 60 40
WSE + smoking 86 39.5 60.5 18 61.1 38.9
CT, computed tomography; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; WSE, wood-smoke exposure.
TABLE 4.  Factors Associated With Overall Survival in All Patients
Median (CI) Months (m)
Univariate A. Multivariate Analysis
p HR CI 95% p
Sex
 Male 13.9 (12.2–15.7) <0.001 1.44 1.15–1.80 0.001
 Female 23.9 (18.2–29.8) — — — —
Age
 ≤ 60 yrs 18.4 (13.7–23.1) 0.117 — — —
 >60 yrs 15.11(11.5–18.7) — — — —
ECOG
 0–1 21.7 (17.9–25.6) 0.0001 1.81 1.44–2.28 0.0001
 2–4 11.3 (9.4–13.2) — — — —
Stage at enrollment
 III 24.0 (16.6–31.3) — — — —
 IV 14.7 (11.9–17.5) 0.003 1.50 1.10–1.90 0.008
Histology
 Adenocarcinoma 20.47 (16.4–24.5) 0.01 1.30 1.0–1.59 0.47
 Other NSCLC 13.3 (11.4–15.2) — — — —
Risk factors
 None 24.8 (17.1–32.6) — 1 — 0.258
 Smoking 13.8 (11.8–15.8) 0.002 1.04 0.74–1.5 —
 WSE 22.7 (16.9–28.6) — 0.76 0.511–1.14 —
 Smoking and WSE 14.3 (8.5–20.0) — 0.884 0.59–1.3 —
Central nervous system metastases
 Present 13.8 (9.9–17.7) 0.22 — — —
 Absent 18.1 (13.7–22.4) — — — —
CI, confidence interval; HR, hazard ratio; NSCLC, non–small-cell lung cancer; WSE, wood-smoke exposure.
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emphysema18; it is also known that exposure to both factors 
increases the risk of developing lung cancer (such risk increas-
ing 1.8–3.4 times for passive smoking).19 WSE is an almost 
exclusive problem for developing countries and, although not 
very well studied, it is estimated that up to 16% of households 
use wood as fuel for heating and cooking in some parts of 
Mexico. High WSE frequency has also been reported in China.20
Thirty-five percent of our patients, mostly women, had a 
history of WSE. Our patient group’s relatively low smoking fre-
quency (58%) was also interesting when compared with reports 
from Europe or North America where such association may reach 
85%.21 Only 19.4% of lung cancer patients in our study group 
had no smoking or WSE history. As opposed to smokers, WSE 
was associated with NSCLC, mainly with adenocarcinoma histol-
ogy. There has been a shift in the histologic frequency of ciga-
rette-smoking–associated lung cancer during the past decades to 
less squamous histology and more adenocarcinoma being found, 
probably associated with changes in substances added to ciga-
rette tobacco. Regarding WSE, polycyclic aromatic hydrocarbons 
(PAHs) or their metabolites possibly penetrate lung tissue more 
deeply, giving rise to peripheral tumors promoting adenocarci-
noma histology.22 Similar to our results, WSE studies on mice 
have also reported the rise of lung adenocarcinoma in  mice.23
WSE-promoted mechanisms or lung carcinogenesis are 
not well known; however, a recent study of women from a 
Chinese WSE region revealed higher DNA adduct numbers 
compared with women from Beijing who used natural gas for 
cooking.24 Higher P53 and MDM2 protein levels have been 
reported in lung cancer patients reporting WSE.25,26 WSE is 
known to promote p16 and GATA promoter methylation11; 
such molecular modifications can be associated with byprod-
ucts of wood burning, such as benzene, 1,3-butadiene, form-
aldehyde, and acetaldehyde—carcinogens that are known 
to increase p53 phosphorylation.10 Other studies have sug-
gested that NSCLC molecular genesis in nonsmoking patients 
involves many p53 mutations, chromosome 16p abnormali-
ties, and low methylation index.27–30 However, none of these 
abnormalities have been linked to altered EGFR-TKI RR. 
Our group has conducted a clinical trial using EGFR-TKI 
(erlotinib) as treatment for patients progressing to first- or 
second-line chemotherapy; 28% of patients had lung cancer-
associated WSE, which was associated with better response to 
erlotinib and improved PFS. Univariate analysis found similar 
response-predictive factors to those previously reported, such 
as being female, having adenocarcinoma, and being a non-
smoker. Nonetheless, after adjusting for sex, ECOG status, 
and histological type, it was found that a background of WSE 
was the most important independent factor associated with 
longer survival and response, having 83.3% overall response 
and 17.6 months PFS.15 Similar studies have reported that 
WSE is a predictor of gefitinib responsiveness.20
It has already become well established that EGFR gene 
mutations confer special sensitivity on TKIs such as gefitinib, 
erlotinib, and afatinib,12 leading to 60% to 80% objective 
response and 8 to 16.5 month PFS rates.31–33 KRAS-mutation 
presence is considered to predict a lack of response to EGFR-
TKI–targeted therapy.14 It was found that WSE was an inde-
pendent factor for increased EGFR-mutation frequency and 
decreased KRAS-mutation frequency, thereby explaining 
increased EGFR-TKIs response. Compounds found in WSE, 
such as PAH, may increase cellular proliferation through 
an interaction with an EGFR-related pathway and thymoma 
viral oncogene homologue serine/threonine protein kinase.34 
Genetic variation in enzymes responsible for activating and 
detoxifying PAHs present in these environments may alter 
susceptibility in individuals who are exposed to coal, wood, 
and biomass smoke, as well as  cooking-oil fumes such as 
Glutathione S-transferases.35 However, this is the first report 
to our knowledge of enhanced EGFR-mutation frequency in 
patients having a history of WSE compared with patients lack-
ing exposure background (27.5 cf. 55.4) and may also be the 
explanation for the association between WSE and response 
to EGFR-TKI. The higher frequency of EGFR mutations in 
WSE patients cannot be solely attributed to inhaling smoke 
because people with direct smoke aspiration and passive ciga-
rette smokers are known to have the same mutation profile.36
No significant difference was found regarding cytotoxic 
therapy response between patients with and without WSE; 
however, some studies have indicated that patients harboring 
EGFR-mutations respond better to chemotherapy than those 
who do not.33 Another study has suggested that patients hav-
ing a WSE background respond better to chemotherapy than 
TKIs.36,37 We observed that the OS of patients with WSE has a 
similar behavior to that of patients who did not have any asso-
ciated risk factors (Fig. 1); although not significant in the mul-
tivariate analysis, this increase in OS compared with those with 
a history of smoking was probably related to increased EGFR-
TKI-treated patients’ RR because of its association with a 
higher frequency of EGFR mutation and less KRAS frequency.
Our group has observed increased EGFR-mutation per-
centage in Mexican and Peruvian populations when genotyping 
a large Latin American lung cancer population.32 Such an obser-
vation may be attributed to ethnic differences and risk factors 
for lung cancer in both populations, such as WSE. Also, the his-
tory of tuberculosis has been associated with more frequency of 
EGFR mutations in NSCLC.38
FIGURE 1. Overall survival of all patients.
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Our study was limited as the presence of EGFR and 
KRAS mutations could not be determined in all patients 
because many of them had already been diagnosed before 
coming to our institution and biopsies could not be repeated. 
Our results suggested that lung carcinogenesis was different 
for patients having a cigarette-smoking background than those 
having a history of WSE. Different clinical and pathological 
patterns were found for these two groups of patients. WSE 
should thus be considered as being highly associated with the 
presence of EGFR- mutations and decreased KRAS mutations 
(along with adenocarcinoma-type histology, being female, 
having Asian ethnicity, and no history of cigarette smoking).
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